Today

VivoSim Labs is conducting a best efforts offering of units, with significant potential dilution from common warrants that include a cashless exercise provision.

VivoSim Labs is registering a mixed offering of common stock, pre-funded warrants, and common warrants, with a significant potential for future dilution from warrant exercises.

The company is registering a primary offering of common stock and pre-funded warrants, but key terms like share count and price are still pending.

HCW Biologics Inc.'s S-1/A registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

HCW Biologics filed an S-1/A to register up to 7.69 million Units, each with a share or pre-funded warrant and a common stock warrant, indicating substantial potential dilution.

Liminatus Pharma, Inc.'s S-1 registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

Liminatus Pharma's mixed offering of common stock, pre-funded warrants, and accompanying warrants presents substantial potential dilution, with contingent exercise terms.

Ernexa Therapeutics Inc.'s S-1/A registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

Ernexa Therapeutics is offering up to 13.6 million units and additional agent shares, creating substantial potential dilution, with an assumed offering price of $0.92 per unit.

Iveda Solutions, Inc.'s S-1/A registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

This mixed offering includes a primary sale of common stock or pre-funded warrants, accompanied by Series X Warrants and Placement Agent Warrants, creating substantial potential dilution.

Picard Medical, Inc.'s S-1/A registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

Picard Medical is offering 21.1 million shares or pre-funded warrants, plus 42.2 million underlying common warrants, which could result in substantial dilution.

BIOVIE INC.'s S-1/A registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

BioVie is offering 1.99 million Units or Pre-funded Units, each with a warrant, at an assumed price of $7.55 per Unit, with final pricing pending.

RYVYL Inc.'s S-1/A registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

RYVYL Inc. is offering up to $8 million in units, including pre-funded warrants with a nominal exercise price, leading to substantial potential dilution.

Soluna Holdings, Inc's S-1/A registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

Sharps Technology Inc.'s S-1/A registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

Smith Micro Software registered 18.2 million shares for resale, representing a substantial overhang from convertible notes and warrants.